Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targetsD.R. Davies, Thale C. Jarvis|Proceedings of the National Academy of Sciences|2012Cited by 254
Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut MicrobiotaBarbara Lomeli, Nebojša Janjić, Jared Schettler et al.|Antimicrobial Agents and Chemotherapy|2019Cited by 38
Ribozymes as Tools for Therapeutic Target Validation in ArthritisThale C. Jarvis, Craig M. Flory|The Journal of Immunology|2000Cited by 16